^
Association details:
| Biomarker: | PCSK9 underexpression |
|---|---|
| Cancer: | Bladder Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NG12 - From cholesterol regulation to tumor suppression: Pcsk9 as a novel target for cancer immunotherapy
Published date:
03/10/2021
Excerpt:
TCGA analyses demonstrated that low expression of Pcsk9 predicted a significantly prolonged overall survival in nine malignancies including liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM), uveal melanoma (UVM), bladder urothelial carcinoma (BLCA), lung adenocarcinoma (LUAD), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), and ovarian carcinoma (OV).
